title: In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes.
abstract: NXL104, a novel β-lactamase inhibitor, was tested at a constant concentration of 4 μg/ml in combination with ceftazidime (CAZ), with and without added metronidazole, against 396 β-lactamase-producing strains of anaerobic bacteria. MIC(50)/MIC(90) values for Bacteroides fragilis and the B. fragilis group were 8/16 and 64/>128 μg/ml, respectively. Although CAZ-NXL104 had limited activity against most anaerobic strains, in combination with metronidazole it shows potential for treating mixed infections involving resistant Enterobacteriaceae and anaerobes.
authors.affiliation: RM Alden Research Laboratory, Culver City, California 90230, USA. d.m.citron@att.net
authors.forename: Diane M
authors.initials: DM
authors.lastname: Citron
authors.forename: Kerin L
authors.initials: KL
authors.lastname: Tyrrell
authors.forename: Vreni
authors.initials: V
authors.lastname: Merriam
authors.forename: Ellie J C
authors.initials: EJ
authors.lastname: Goldstein
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053961:Azabicyclo Compounds / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000201:enzymology*; D002442:Ceftazidime / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology; D008795:Metronidazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests
chemical_list: D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D008795:Metronidazole; C543519:avibactam; D002442:Ceftazidime